Compare ADMA Biologics Inc (ADMA) vs Sunrun Inc (RUN) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Sunrun (RUN) trades at $12.97, up 1.81% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamental metrics with a low P/E of 6.09 and robust profitability margins, while recent news highlights the company's strategic partnership with Tesla for virtual power plants targeting AI data center demand. Cash flow trends show significant investing activity with positive net cash flow.

The outlook remains cautiously optimistic with analyst consensus at Buy (62%) and a $17.58 price target, though technical weakness and negative operating cash flow present near-term risks. The Tesla partnership offers growth potential in energy infrastructure, but execution risks and market volatility require monitoring.